Drug Absorption Across Biological Membranes

For a drug to exert its therapeutic effect, it must first reach its site of action in the body. This journey almost always begins with crossing a biological barrier, most commonly the lipid bilayers of the intestinal epithelium. Understanding the mechanisms by which drugs traverse these membranes—passive diffusion, carrier-mediated transport, and paracellular transport—is foundational to predicting a drug's behavior, optimizing its formulation, and anticipating potential drug interactions. Mastering these concepts explains why some drugs are well-absorbed as pills while others must be injected, and why the absorption of some can be dangerously altered by food or other medications.

The Foundation: Passive Diffusion Through Lipid Bilayers

The most common pathway for drug absorption is passive diffusion. This is a spontaneous process where drug molecules move from an area of higher concentration (e.g., the intestinal lumen) to an area of lower concentration (the bloodstream), directly through the lipid core of the cell membrane. No cellular energy is required, and the process does not involve specific membrane proteins.

The rate of passive diffusion is governed by Fick's law of diffusion. In its simplified form for biological membranes, it states that the flux ($J$) of a drug is proportional to the membrane permeability coefficient ($P$) and the concentration gradient ($\Delta C$). This can be expressed as: $$J=P\times \Delta C$$

Permeability ($P$) itself is determined by the drug's physicochemical properties, primarily its lipid solubility and molecular size. The pH-partition hypothesis is key here: only the uncharged, non-polar form of a drug can readily dissolve in the lipid bilayer. For a weak acid (like aspirin), the uncharged form predominates in acidic environments (the stomach), favoring absorption there. For a weak base, the uncharged form is more prevalent in basic environments (the small intestine). Therefore, a drug's pKa and the environmental pH jointly dictate what fraction of the drug is in the absorbable, lipid-soluble form.

Specialized Pathways: Carrier-Mediated Transport

Not all drugs can rely on passive diffusion, especially those that are large, highly polar, or ionized at physiological pH. These molecules utilize carrier-mediated transport, which involves specific membrane proteins that bind and shuttle the drug across the membrane. This category is divided into facilitated diffusion and active transport.

Facilitated diffusion, mediated by Solute Carrier (SLC) transporters, moves molecules down their concentration gradient without energy expenditure. Think of it as a protein forming a specific gate that opens for a particular passenger. A key clinical example is the absorption of levodopa, the precursor to dopamine, via amino acid transporters in the intestine.

Active transport moves molecules against their concentration gradient, requiring energy from ATP hydrolysis. The ATP-Binding Cassette (ABC) transporter family is a major group of active transporters. The most pharmacologically significant member is P-glycoprotein (P-gp), an efflux pump that actively transports drugs out of cells and back into the intestinal lumen or away from sensitive sites like the brain. P-gp plays a critical role in limiting absorption and distribution for many drugs, including digoxin, cyclosporine, and certain anticancer agents. Inhibition or induction of P-gp by other drugs is a major source of clinically significant drug interactions.

The Paracellular Route and Membrane Permeability Factors

A minor but important pathway for very small, hydrophilic molecules is paracellular transport. Here, drugs pass between adjacent epithelial cells through tight junctions. This aqueous pore pathway is size-restrictive; only drugs with a low molecular weight (typically less than 200-300 Da) and high polarity can use it effectively. Water-soluble vitamins and some ions are examples. The permeability of this route can be transiently increased by certain absorption enhancers or in disease states that disrupt tight junction integrity.

Overall membrane permeability is a composite of all these routes. Key factors influencing it include:

• Molecular weight/size: Smaller molecules diffuse more easily.
• Lipophilicity: Measured by the partition coefficient, this determines solubility in the lipid bilayer.
• Degree of ionization: Dictated by pKa and pH, as described.
• Surface area: The immense surface area of the small intestinal villi vastly enhances absorption compared to the stomach.
• Presence of specific transporters: SLC transporters increase, while ABC efflux pumps like P-gp decrease, effective permeability.

Saturation Kinetics and Bioavailability Implications

A critical distinction between passive and carrier-mediated transport is the concept of saturation. Passive diffusion rates increase linearly with drug concentration (governed by Fick's law). In contrast, carrier-mediated processes have a finite number of transporter proteins. Once all transporters are occupied, the system is saturated, and the transport rate reaches a maximum ($V_{max}$). This follows Michaelis-Menten kinetics.

This has direct consequences for intestinal transporter saturation affecting drug bioavailability at high doses. For a drug primarily absorbed via a specific SLC transporter (e.g., gabapentin), increasing the oral dose beyond the transporter's capacity will not lead to a proportional increase in the amount absorbed. The bioavailability (the fraction of dose that reaches systemic circulation) will actually decrease as the dose increases. This non-linear pharmacokinetics is a crucial consideration for dosing. Similarly, efflux pumps like P-gp can also be saturated, which can unexpectedly increase the absorption of a victim drug if a large enough dose is given or if a P-gp inhibitor is co-administered.

Clinical Integration: From Membrane to Patient

These abstract mechanisms have tangible clinical outcomes. Consider the antibiotic ciprofloxacin (a weak base). Its absorption is decreased by dairy products because calcium cations chelate the drug, forming a non-absorbable complex—a factor related to luminal chemistry, not membrane transport. Conversely, the cardiac drug digoxin has its absorption significantly increased by the concurrent use of clarithromycin, an antibiotic that inhibits the P-gp efflux pump in the intestine. This interaction can lead to digitalis toxicity. Furthermore, formulating a drug as a prodrug—an inactive precursor—is a common strategy to improve absorption. Enalapril, for instance, is an ester prodrug that is more lipophilic than the active enalaprilat, allowing for better passive diffusion before being hydrolyzed in the blood.

Common Pitfalls

1. Confusing directionality of transporters: It is easy to remember that SLC transporters bring drugs in, but forgetting that ABC transporters like P-gp pump drugs out is a common error. Always associate P-gp with limiting absorption and distribution.
2. Misapplying the pH-partition hypothesis: Remember that absorption depends on the gradient of the uncharged species. While a weak acid is largely uncharged in the stomach, the immense surface area and longer transit time of the small intestine often make it the primary site of absorption for most orally administered drugs, regardless of pH considerations.
3. Overlooking saturation kinetics: Assuming absorption is always a first-order (linear) process is a mistake. For any drug known to use a specific transporter, you must consider the possibility of dose-dependent, non-linear bioavailability.
4. Equating lipophilicity with absorption: While high lipid solubility aids passive diffusion, an extremely lipophilic drug may become trapped in the membrane or have poor solubility in the gastrointestinal fluids, limiting its availability at the membrane surface. Optimal absorption requires a balance.

Summary

• Passive diffusion, governed by Fick's law and the pH-partition hypothesis, is the most common absorption pathway for small, lipophilic drugs moving down their concentration gradient.
• Carrier-mediated transport via SLC (influx) and ABC (efflux) transporters provides a selective pathway for larger or polar drugs, with the P-glycoprotein efflux pump being a major player in limiting drug absorption and causing interactions.
• Paracellular transport is a minor route limited to very small, hydrophilic molecules passing through tight junctions between cells.
• Key membrane permeability factors include molecular size, lipophilicity, degree of ionization, and the presence of specific transporters.
• Unlike passive diffusion, carrier-mediated transport is saturable, which can lead to dose-dependent bioavailability where increasing the dose does not proportionally increase the amount absorbed.